• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从多个配体复合物结构深入了解布鲁顿酪氨酸激酶的构象灵活性。

Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

机构信息

Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, USA.

出版信息

Protein Sci. 2011 Feb;20(2):428-36. doi: 10.1002/pro.575.

DOI:10.1002/pro.575
PMID:21280133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3048427/
Abstract

Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. We have determined the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chemical classes. Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop. The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homology 2-kinase domain linker. Two novel activation loop conformations and an atypical DFG conformation are observed representing unique inactive states of BTK. Two regions within the activation loop are shown to structurally transform between 3(10)- and α-helices, one of which collapses into the adenosine-5'-triphosphate binding pocket. The first crystal structure of a Tec kinase family member in the pharmacologically important DFG-out conformation and bound to a type II kinase inhibitor is described. The different protein conformations observed provide insights into the structural flexibility of BTK, the molecular basis of its regulation, and the structure-based design of specific inhibitors.

摘要

布鲁顿酪氨酸激酶(BTK)在 B 细胞受体信号转导中发挥关键作用,被认为是淋巴瘤和炎症性疾病有前途的药物靶点。我们已经确定了 BTK 激酶结构域与来自不同化学类别的六种抑制剂复合物的 X 射线晶体结构。五种不同的 BTK 蛋白构象通过结合抑制剂得到稳定,为 Gly-丰富环、螺旋 C、DFG 序列和激活环的结构灵活性提供了见解。构象变化独立于激活环磷酸化发生,与Src 同源 2 激酶结构域接头中结构不变的 WEI 基序无关。观察到两种新型激活环构象和一种非典型 DFG 构象,代表 BTK 的独特非活性状态。激活环内的两个区域被证明在 3(10)-和α-螺旋之间结构转化,其中一个折叠到腺苷-5'-三磷酸结合口袋中。描述了第一个处于药理学上重要的 DFG-out 构象的 Tec 激酶家族成员的晶体结构,并与 II 型激酶抑制剂结合。观察到的不同蛋白质构象为 BTK 的结构灵活性、其调节的分子基础以及基于结构的特异性抑制剂设计提供了见解。

相似文献

1
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.从多个配体复合物结构深入了解布鲁顿酪氨酸激酶的构象灵活性。
Protein Sci. 2011 Feb;20(2):428-36. doi: 10.1002/pro.575.
2
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.人源布鲁顿酪氨酸激酶在活性和非活性构象下的结构揭示了 TEC 家族激酶的激活机制。
Protein Sci. 2010 Mar;19(3):429-39. doi: 10.1002/pro.321.
3
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.BTK 活性位点抑制剂对全长 BTK 构象状态的差异化影响。
Elife. 2020 Nov 23;9:e60470. doi: 10.7554/eLife.60470.
4
Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.布鲁顿酪氨酸激酶(Btk)的自抑制作用及可溶性肌醇六磷酸的激活作用。
Elife. 2015 Feb 20;4:e06074. doi: 10.7554/eLife.06074.
5
Bruton's TK inhibitors: structural insights and evolution of clinical candidates.布鲁顿酪氨酸激酶抑制剂:结构见解与临床候选药物的进化。
Future Med Chem. 2014 Apr;6(6):675-95. doi: 10.4155/fmc.14.24.
6
Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.通过分子动力学模拟比较不可逆抑制剂和可逆抑制剂与布鲁顿酪氨酸激酶的分子间相互作用。
Molecules. 2022 Nov 2;27(21):7451. doi: 10.3390/molecules27217451.
7
X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase.X 染色体骨髓激酶的 X 射线晶体结构:Tec 家族激酶。
Chem Biol Drug Des. 2011 Nov;78(5):739-48. doi: 10.1111/j.1747-0285.2011.01230.x. Epub 2011 Sep 21.
8
Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.发现 5-苯氧基-2-氨基吡啶衍生物作为有效的和选择性的布鲁顿酪氨酸激酶不可逆抑制剂。
Int J Mol Sci. 2020 Oct 28;21(21):8006. doi: 10.3390/ijms21218006.
9
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.与来自p120cbl的富含脯氨酸的肽复合的人BTK SH3结构域的溶液结构
J Biomol NMR. 2000 Apr;16(4):303-12. doi: 10.1023/a:1008376624863.
10
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.发现一类新型共价双抑制剂,靶向蛋白激酶 BMX 和 BTK。
Int J Mol Sci. 2020 Dec 4;21(23):9269. doi: 10.3390/ijms21239269.

引用本文的文献

1
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.通过计算机药物重定位策略发现潜在的布鲁顿酪氨酸激酶抑制剂。
Sci Rep. 2023 Oct 17;13(1):17684. doi: 10.1038/s41598-023-44956-0.
2
Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor.布鲁顿酪氨酸激酶(BTK)抑制剂一系列潜在前药的设计、合成与评价
Front Pharmacol. 2023 Mar 8;14:1162216. doi: 10.3389/fphar.2023.1162216. eCollection 2023.
3
Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.通过分子动力学模拟比较不可逆抑制剂和可逆抑制剂与布鲁顿酪氨酸激酶的分子间相互作用。
Molecules. 2022 Nov 2;27(21):7451. doi: 10.3390/molecules27217451.
4
Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.人源蛋白激酶前口袋 N 端帽半胱氨酸的反应活性。
J Med Chem. 2022 Jan 27;65(2):1525-1535. doi: 10.1021/acs.jmedchem.1c01186. Epub 2021 Oct 14.
5
Disrupting enzyme fluidity.破坏酶的流动性。
Elife. 2021 Jan 25;10:e65221. doi: 10.7554/eLife.65221.
6
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.BTK 活性位点抑制剂对全长 BTK 构象状态的差异化影响。
Elife. 2020 Nov 23;9:e60470. doi: 10.7554/eLife.60470.
7
Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.发现 5-苯氧基-2-氨基吡啶衍生物作为有效的和选择性的布鲁顿酪氨酸激酶不可逆抑制剂。
Int J Mol Sci. 2020 Oct 28;21(21):8006. doi: 10.3390/ijms21218006.
8
Discovery and Evaluation of Pyrazolo[3,4-]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.吡唑并[3,4 - ]哒嗪酮作为一种强效口服活性不可逆BTK抑制剂的发现与评价
ACS Med Chem Lett. 2019 Dec 11;11(10):1863-1868. doi: 10.1021/acsmedchemlett.9b00395. eCollection 2020 Oct 8.
9
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies.一种非共价抑制剂 XMU-MP-3 克服了 B 细胞恶性肿瘤中伊布替尼耐药的 Btk 突变。
Br J Pharmacol. 2019 Dec;176(23):4491-4509. doi: 10.1111/bph.14809. Epub 2019 Dec 9.
10
Millisecond dynamics of BTK reveal kinome-wide conformational plasticity within the apo kinase domain.BTK 的毫秒动力学揭示了无配体激酶结构域内的激酶组构象可塑性。
Sci Rep. 2017 Nov 15;7(1):15604. doi: 10.1038/s41598-017-10697-0.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.治疗类风湿关节炎的一种口服脾脏酪氨酸激酶(Syk)抑制剂。
N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.
3
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.布鲁顿酪氨酸激酶作为治疗白血病和淋巴瘤以及炎症性疾病和自身免疫的分子靶点。
Expert Opin Ther Pat. 2010 Nov;20(11):1457-70. doi: 10.1517/13543776.2010.517750. Epub 2010 Sep 10.
4
Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.IL-2 诱导的 T 细胞激酶复合物与抑制剂的晶体结构:深入了解合理药物设计和活性调节。
Chem Biol Drug Des. 2010 Aug;76(2):154-63. doi: 10.1111/j.1747-0285.2010.00993.x. Epub 2010 Jun 9.
5
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.人源布鲁顿酪氨酸激酶在活性和非活性构象下的结构揭示了 TEC 家族激酶的激活机制。
Protein Sci. 2010 Mar;19(3):429-39. doi: 10.1002/pro.321.
6
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.经临床评估用于治疗慢性炎症性疾病的选择性p38α抑制剂。
J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906.
7
A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.一种新型适合吸入的 SYK 激酶抑制剂:R-343(?)-WO-2009031011。
Expert Opin Ther Pat. 2009 Oct;19(10):1469-72. doi: 10.1517/13543770903059281.
8
Bruton's tyrosine kinase as a drug discovery target.布鲁顿酪氨酸激酶作为药物研发靶点
Drug News Perspect. 2008 Sep;21(7):357-62. doi: 10.1358/dnp.2008.21.7.1255308.
9
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.通过对三种抑制剂复合物的晶体学分析获得的强效脾酪氨酸激酶抑制剂设计的结构见解。
Chem Biol Drug Des. 2009 Apr;73(4):466-70. doi: 10.1111/j.1747-0285.2009.00785.x. Epub 2009 Feb 7.
10
Structural biology contributions to tyrosine kinase drug discovery.结构生物学对酪氨酸激酶药物研发的贡献。
Curr Opin Cell Biol. 2009 Apr;21(2):280-7. doi: 10.1016/j.ceb.2009.01.012. Epub 2009 Feb 7.